SARS-COV-2-FIGHTING HUMANIZED MULTIVALENT BINDING PROTEIN AND USE THEREOF

The present invention relates to the technical field of antibodies, and specifically relates to a SARS-CoV-2-fighting humanized multivalent binding protein and a use thereof. The multivalent binding protein can effectively block the binding of RBD proteins of wild-type SARS-CoV-2 and the Delta and O...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	HUO, Yongting, LU, Di
Format:	Patent
Sprache:	chi ; eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to the technical field of antibodies, and specifically relates to a SARS-CoV-2-fighting humanized multivalent binding protein and a use thereof. The multivalent binding protein can effectively block the binding of RBD proteins of wild-type SARS-CoV-2 and the Delta and Omicron variants of SARS-CoV-2 with human ACE2 receptor proteins; compared with monovalent binding proteins, the present multivalent binding protein has more prominent SARS-CoV-2 neutralizing activity and can be widely used in SARS-COV-2 prevention and treatment. La présente invention concerne le domaine technique des anticorps, et concerne spécifiquement une protéine de liaison multivalente humanisée anti-SARS-CoV-2 et son utilisation. La protéine de liaison multivalente peut bloquer efficacement la liaison de protéines RBD du SARS-CoV-2 de type sauvage et des variants Delta et Omicron du SARS-CoV-2 avec des protéines du récepteur ACE2 humain ; par comparaison avec des protéines de liaison monovalentes, la présente